Clinical and histopathological spectrum of IgA nephropathy in Kuwait

Affiliations


Abstract

Background: Little is known about the nature and the course of IgA nephropathy (IgAN) in Arab countries. The aim of this work was to study the spectrum of clinical presentation and histopathological findings at our institution.

Design and setting: Retrospective review, all renal biopsies at the Mubarak Al Kabeer Hospital between January 2000 and December 2004.

Methods: Cases of IgA nephropathy were selected, and their medical records and biopsy findings were reviewed.

Results: Eighty patients (9.2% of all native kidney biopsies) were diagnosed to have IgAN nephropathy. Sixty-nine biopsies were included in the study;11 were excluded. Forty-three (62.3%) patients were male and 26 (37.7) patients were female. Fifty (72.5%) patients were below the age of 40 years. Mean (SD) duration of follow-up was 3.6 (1.3) years. The first presentation included nephritic-range proteinuria (49.3%) and renal impairment (50.7%). During the follow-up period, 56 (81.2%) patients were stable or improved. Hass classification of biopsies showed 36.2% had class I, 27.5% had class II, 13.0% had class III, 5.8% had class IV, and 17.4% had class V IgAN. Females had milder forms of the disease than males. Macroscopic hematuria and renal impairment at presentation were seen more in patients with class IV and V IgAN. The presenting serum creatinine and uric acid values were higher in those with Hass classes III to V. Deterioration of renal function during the follow-up period was more significant in the presence of hypertension, renal impairment, or macroscopic hematuria at the time of biopsy .

Conclusion: The prevalence of IgAN in Kuwait is about 9.2%. Renal impairment or macroscopic hematuria at presentation was seen in patients with more aggressive renal lesions and contributed to poor outcome.


Figures


Similar articles

Clinicopathological features and outcomes of IgA nephropathy with hematuria and/or minimal proteinuria.

Tan M, Li W, Zou G, Zhang C, Fang J.Kidney Blood Press Res. 2015;40(2):200-6. doi: 10.1159/000368495. Epub 2015 Apr 6.PMID: 25924707

Indian scenario of IgA nephropathy: a systematic review and meta-analysis.

Khairwa A.Afr Health Sci. 2021 Mar;21(1):159-165. doi: 10.4314/ahs.v21i1.21.PMID: 34394293 Free PMC article.

Factors associated with progression of IgA nephropathy are related to renal function--a model for estimating risk of progression in mild disease.

Rauta V, Finne P, Fagerudd J, Rosenlöf K, Törnroth T, Grönhagen-Riska C.Clin Nephrol. 2002 Aug;58(2):85-94. doi: 10.5414/cnp58085.PMID: 12227693

IgA nephropathy: clinical features and natural history--a pediatric perspective.

Hogg RJ.Am J Kidney Dis. 1988 Nov;12(5):358-61. doi: 10.1016/s0272-6386(88)80024-6.PMID: 3055957 Review.

Clinical features and natural history in adults with IgA nephropathy.

D'Amico G.Am J Kidney Dis. 1988 Nov;12(5):353-7. doi: 10.1016/s0272-6386(88)80023-4.PMID: 3055956 Review.


Cited by

Podocytes are likely the therapeutic target of IgA nephropathy with isolated hematuria: Evidence from repeat renal biopsy.

Luo MN, Yin Y, Li S, Hao J, Yao C, Xu YZ, Liu HF, Yang L.Front Pharmacol. 2023 Apr 7;14:1148553. doi: 10.3389/fphar.2023.1148553. eCollection 2023.PMID: 37089927 Free PMC article.

Immunoglobulin A (IgA) Nephropathy: A Clinicopathologic Study in a Tertiary Care Center in Saudi Arabia.

Bokhary OA, Alhozali HM, Alghamdi MK, Abulfaraj AM, Alkhallagi AS, Aldharrab AS, Alyahya FS, Al Zahrani RA.Cureus. 2021 Nov 10;13(11):e19445. doi: 10.7759/cureus.19445. eCollection 2021 Nov.PMID: 34912596 Free PMC article.

Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis.

He P, Wang H, Huang C, He L.Ren Fail. 2021 Dec;43(1):488-499. doi: 10.1080/0886022X.2021.1879852.PMID: 33685345 Free PMC article.


KMEL References


References

  1.  
    1. Berger J, Hinglais N. Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris) 1968;74:694–5. - PubMed
  2.  
    1. Donadio J, Grande J. IgA Nephropathy. N Engl J Med. 2002;347:738–48. - PubMed
  3.  
    1. Eitner F, Ackermann D, Hilgers RD, Floege J. Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: Rationale and study protocol. J Nephrol. 2008;21:284–9. - PubMed
  4.  
    1. Bruce AJ, Jan N. IgA nephropathy: An update. Curr Opin Nephrol Hypertens. 2004;13:171–9. - PubMed
  5.  
    1. Baek JE, Chang JW, Min WK, Cho YM, Park JS, Kim SB. Serum high sensitivity C-reactive protein is not increased in patients with IgA nephropathy. Nephron Clin Pract. 2008;108:C35–40. - PubMed
  6.  
    1. Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005;68:802–12. - PubMed
  7.  
    1. Frisch G, Lin J, Rosenstock J, Markowitz G, D’Agati V, Radhakrishnan J, et al. Mycophenolate mofetil (MMF) vs Placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial. Nephrol Dial Transplant. 2005;20:2139–45. - PubMed
  8.  
    1. Hass M. Histologic subclassification of IgA nephropathy: A clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29:829–42. - PubMed
  9.  
    1. Navas-Palacios JJ, Gutierrez-Millet V, Usera-Sárrage G, Garzón-Martin A. IgA nephropathy: An ultrastructural study. Ultrastruct Path. 1981;2:151–61. - PubMed
  10.  
    1. Seeman T, Pohl M, John U, Dusek J, Vondrák K, Janda J, et al. Ambulatory blood pressure, proteinuria and uric acid in children with IgA nephropathy and their correlation with histopathological findings. Kidney Blood Press Res. 2008;31:337–42. - PubMed
  11.  
    1. Cook HT. Pathological predictors of prognosis in immunoglobulin A nephropathy: A review. Curr Opin Nephrol Hypertens. 2009;18:212–9. - PubMed
  12.  
    1. Katafuchi R, Ninomiya T, Mizumasa T, Ikeda K, Kumagai H, Nagata M, et al. The improvement of renal survival with steroid pulse therapy in IgA nephropathy. Nephrol Dial Transplant. 2008;23:3915–20. - PMC - PubMed
  13.  
    1. Kim SM, Moon KC, Oh KH, Joo KW, Kim YS, Ahn C, et al. Clinicopathologic characteristics of IgA nephropathy with steroid-responsive nephrotic syndrome. J Korean Med Sci. 2009;24:S44–9. - PMC - PubMed
  14.  
    1. Nakayama K, Ohsawa I, Maeda-Ohtani A, Murakoshi M, Horikoshi S, Tomino Y. Predictors of diagnosis of immunoglobulin A nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading. J Clin Lab Anal. 2008;22:114–8. - PMC - PubMed
  15.  
    1. Ballardie FW, Cowley RD. Prognostic indices and therapy in IgA nephropathy: Toward a solution. Kidney Int. 2008;73:249–51. - PubMed
  16.  
    1. Berger J. Idiopathic mesangial deposition of IgA, in Nephropathy. In: Hamburger J, Crosnier J, Grunfeld JP, editors. New York: John Wiley and Sons; 1979. pp. 535–41.
  17.  
    1. A multicenter study of IgA nephropathy in children. A report of the South West Pediatric Nephrology Study Group. Kidney Int. 1982;22:643–52. - PubMed
  18.  
    1. Shimaada H, Imai N, Miyakawa Y, et al. [AUTHOR: Please provide remaining author names] Clinical spectrum of IgA nephropathy.A clinicopathological study of adult Japanese IgA nephropathy patients: Early stage cases and cases with exacerbations. Nephrology. 1997;3:S701–7.
  19.  
    1. D’Amico G, Imbasciati E, Barbiano Di Belgioioso G, Bertoli S, Fogazzi G, Ferrario F, et al. IgA mesangial nephropathy: Clinical and histological study of 374 patients. Medicine. 1985;64:49–60. - PubMed
  20.  
    1. Reich HN, Troyanov S, Scholey JW, Cattran DC. Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177–83. - PubMed
  21.  
    1. Rositto AE, Cobenas C, Drut R. Linear IgA disease of childhood developing IgA nephropathy. Pediatr Dermatol. 2008;25:339–40. - PubMed
  22.  
    1. Mitsuiki K, Harada A, Okura T, Higaki J. Histopathologically advanced IgA nephropathy treated successfully with prednisolone and cyclophosphamide. Clin Exp Nephrol. 2007;11:297–303. - PubMed
  23.  
    1. Bennett WM, Kincaid-Smith P. Macroscopic hematuria in mesangial IgA nephropathy: Correlation with glomerular crescents and renal dysfunction. Kidney Int. 1983;23:393–400. - PubMed
  24.  
    1. Clarkson AR, Seymour AE, Thompson AJ, Haynes WD, Chan YL, Jackson B, et al. IgA nephropathy; a syndrome of uniform morphology, diverse clinical features and uncertain prognosis. Clin Nephrol. 1977;8:459–71. - PubMed
  25.  
    1. Haas M, Rahman MH, Cohn RA, Fathallah-Shaykh S, Ansari A, Bartosh SM. IgA nephropathy in children and adults.Comparison of histopathologic features and clinical outcomes. Nephrol Dail Transplant. 2008;23:2537–45. - PubMed
  26.  
    1. Myllymäki J, Honkanen T, Syrjänen J, Helin H, Rantala I, Pasternack A, et al. Uric acid correlates with severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant. 2005;20:89–95. - PubMed
  27.  
    1. Moura IC, Benhamou M, Launay P, Vrtovsnik F, Blank U, Monteiro RC. The glomerular response to IgA deposition in IgA nephropathy. Semin Nephrol. 2008;28:88–95. - PubMed
  28.  
    1. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J kidney Dis. 2001;38:728–35. - PubMed
  29.  
    1. Van der Peet J, Arisz L, Brentjens JR, Marrink J, Hoedemaeker PJ. The clinical course of IgA nephropathy in adults. Clin Nephrol. 1977;8:335–40. - PubMed
  30.  
    1. Roufosse CA, Cook HT. Pathological predictors of prognosis in immunoglobulin A nephropathy: A review. Curr Opin Nephrol Hypertens. 2009;18:212–9. - PubMed